Datum | Källa | Rubrik | Typ | Alternativ | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-05-06 | Alzinova | BioStock: Alzinovas avgående vd kommenterar bolagets potential | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-26 | Alzinova | KALLELSE TILL ÅRSSTÄMMA I ALZINOVA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-26 | Alzinova | NOTICE OF ANNUAL GENERAL MEETING IN ALZINOVA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-26 | Alzinova | Styrelsen beslutar om en företrädesemission av aktier om cirka 34,4 MSEK | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-26 | Alzinova | The Board of Directors resolves on a rights issue of shares of approximately SEK 34.4 million | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
Pressreleaser |
The Board of Directors resolves on a rights issue of shares of approximately SEK 34.4 millionNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA, THE UNITED KINGDOM, HONG KONG, RUSSIA, BELARUS, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES THAN SUCH MEASURES WHICH FOLLOWS FROM SWEDISH REGULATIONS. The Board of Directors of Alzinova AB (publ) (“Alzinova” or the “Company”) has today resolved, with authorisation from the Annual General Meeting of 2023, on a rights issue of shares with pre-emption rights for the shareholders of approximately SEK 34.4 million (the “Rights Issue”). Prior to the Rights Issue, the Company has received subscription and underwriting commitments amounting to SEK 34.4 million, corresponding to 100 percent of the Rights Issue. Summary
Background and rationale in summary Alzinova is also developing ALZ-201, an oligomer-specific monoclonal antibody that can be used as a standalone disease-modifying therapy or as a complement to ALZ-101 for the treatment of Alzheimer’s disease. The proceeds, after issuing costs, from the Rights Issue shall primarily be used for:
Terms for the Rights Issue
Subscription commitments and underwriting commitments Due to related parties to the Company being part of the underwriting consortium, the resolution on the issue to underwriters will be made at the Company’s Annual General Meeting. Notice of the Annual General Meeting will be published through a separate press release. The Board of Directors considers it favorable for the Company to offer underwriters compensation in the Company’s own shares as it has a positive effect on the Company’s liquidity. The subscription price in the directed issue to the underwriters was negotiated at arm’s length in connection with the procurement of the underwriting commitments, which took place in consultation with the financial advisor and after an analysis of customary market factors. The Board of Directors’ assessment is that the subscription price, and other conditions in the directed issue to the underwriters, against this background, are market conformant. Some underwriters have provided underwriting commitments which could result in an ownership that exceed ten or twenty percent of the votes in the Company if the Rights Issue is only subscribed up to the level covered by subscription and underwriting commitments. To the extent the underwriters’ fulfilment of such commitment entails that the investment must be approved by the Inspectorate of Strategic Products (Sw. Inspektionen för strategiska produkter) in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. lagen (2023:560) om granskning av utländska direktinvesteringar), such part of the commitment is conditional upon notification that the application of the transaction is left without action or that approval has been obtained from the Inspectorate of Strategic Products. Prospectus Preliminary timetable
Advisors For more information, please contact: About Alzinova AB Important Information This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed in Within the European Economic Area, no offer is made to the public of securities in any country other than Sweden. In other Member States of the European Union, such an offer may only be made in accordance with the exceptions in the Prospectus Regulation (EU) 2017/1129. As the Company has made the assessment that the Company conducts activities worthy of protection under the Swedish Screening of Foreign Direct Investments Act (Sw. lagen (2023:560) om granskning av utländska direktinvesteringar), certain investments in the Company may require review by the Swedish Inspectorate of Strategic Products. For more information, please visit the Swedish Inspectorate of Strategic Products’ website, www.isp.se, or contact the Company. This press release contains certain forward-looking information that reflects the Company’s present view of future events as well as financial and operational development. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information. |
||||||||||||||||||
2024-04-25 | Alzinova | Kristina Torfgård lämnar VD-posten på Alzinova AB i juli 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-25 | Alzinova | Kristina Torfgård leaves the CEO position at Alzinova AB in July 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-22 | Alzinova | BioStock: Alzinovas CSO kommenterar nya analysdata för ALZ-101 i Alzheimers sjukdom | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-11 | Alzinova | Alzinova: Fördjupad analys påvisar positiv trend för biomarkörer | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-11 | Alzinova | Alzinova: In-depth analysis shows positive trend in biomarkers | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-10 | Alzinova | BioStock: Alzinova når ytterligare milstolpe i Alzheimerstudie | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-04 | Alzinova | Alzinova - All patients in the extension part of the phase 1b study have received their last dose | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-04 | Alzinova | Alzinova - Samtliga patienter i fas 1b-studiens förlängningsdel har fått sin sista dos | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-03-08 | Alzinova | Alzinova appoints Erik Kullgren as interim CFO | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-03-08 | Alzinova | Alzinova utser Erik Kullgren som interim CFO | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-03-05 | Alzinova | Alzinova presenterar på investerarträffar i mars | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-03-05 | Alzinova | Alzinova presents at investor meetings in March | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-03-04 | Alzinova | BioStock: Alzinova siktar på partnerskap för Alzheimerstudien | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-29 | Penser Future by Carnegie | Penser Future by Carnegie: Alzinova - Huvudfokus för 2024 är att teckna ett partneravtal | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-28 | Redeye | Redeye: Alzinova Q4 – With wind in the sails | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-28 | Alzinova | Alzinova offentliggör bokslutskommuniké för 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-28 | Alzinova | Alzinova publishes Year-end report 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-16 | Alzinova | BioStock: Alzinova får grönt ljus att öka dosen i Alzheimerstudie | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-13 | Alzinova | Alzinova receives regulatory approval to evaluate a higher dose | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-13 | Alzinova | Alzinova får myndighetsgodkännande att utvärdera en högre dos | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-07 | Alzinova | Alzinova till BioStock: "Vi har ett starkt case med vår Alzheimerkandidat" | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-01-30 | Alzinova | Alzinova: Primary analysis confirms positive phase 1b results with ALZ-101 against Alzheimer’s | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-01-30 | Alzinova | Alzinova: Primär analys bekräftar positiva fas 1b-resultat med ALZ-101 mot Alzheimers | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-01-08 | Alzinova | BioStock: Alzinova's CMO wants to bring forward a vaccine against Alzheimer's | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-11 | Penser Future by Carnegie | Penser Future by Carnegie: Alzinova - Therapeutic Alzheimer's vaccine in the spotlight | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-07 | Penser Future by Carnegie | Penser Future by Carnegie: Intervju med Alzinova - Carnegie Investment Bank - 7 dec 2023 | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-04 | Alzinova | BioStock: Alzinovas vd kommenterar positiva topline-data | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-04 | Redeye | Redeye: Alzinova - Positive topline results | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-01 | Penser Future by Carnegie | Penser Future by Carnegie: Positiva topline-resultat från den kliniska fas Ib-studien - Alzinova | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-01 | Alzinova | Alzinovas CFO avser gå i pension och Bolaget inleder rekryteringsprocessen för en efterträdare | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-01 | Alzinova | Alzinova's CFO plans for retirement and the Company initiates a recruitment process for a successor | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-29 | Alzinova | Alzinova announces positive phase 1b results with the vaccine candidate ALZ-101 against Alzheimer's disease | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-29 | Alzinova | Alzinova meddelar positiva fas 1b-resultat med vaccinkandidaten ALZ-101 mot Alzheimers sjukdom | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-21 | Penser Future | Penser Future: Terapeutiskt vaccin mot Alzheimers sjukdom i fokus - Alzinova AB | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-20 | Alzinova | Alzinova presenterar på Erik Penser Banks Bolagsdag den 23 november | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-20 | Alzinova | Alzinova presents at Erik Penser Bank's Investor Day on November 23rd | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-06 | Alzinova | BioStock: Alzinova om förväntningarna inför BIO-Europe | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-02 | Redeye | Redeye: Alzinova Q3 - All eyes on the readout | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-02 | Alzinova | Alzinova AB delårsrapport för januari - september 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-02 | Alzinova | Alzinova AB interim report January – September 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-24 | Alzinova | Alzinova engages Erik Penser Bank as liquidity provider | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-24 | Alzinova | Alzinova anlitar Erik Penser Bank som likviditetsgarant | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-05 | Alzinova | Alzinova deltar under hösten vid Europas största Life science-konferens och investerarträffar | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-05 | Alzinova | Alzinova will attend Europe's largest Life Science conference and investor meetings this fall | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-28 | Alzinova | BioStock: Alzinova säkrar regulatoriskt stöd från EMA | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-26 | Alzinova | Alzinova receives positive response from the European Medicines Agency EMA | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-26 | Alzinova | Alzinova erhåller positivt svar från European Medicines Agency EMA | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-21 | Alzinova | Alzinova intervjuas hos Redeye i samband med World Alzheimer’s Day | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-21 | Alzinova | Alzinova interviewed by Redeye in connection with World Alzheimer's Day | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-11 | Alzinova | BioStock: Alzinovas vd sammanfattar 2023 och blickar framåt | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-25 | Alzinova | Alzinova inleder samarbete med PolyPeptide | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-25 | Alzinova | Alzinova initiates collaboration with PolyPeptide | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-17 | Redeye | Redeye: Alzinova Q2 2023 - Proactive preparations | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-17 | Alzinova | Alzinova AB delårsrapport för januari - juni 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-17 | Alzinova | Alzinova AB interim report January – June 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-10 | Alzinova | BioStock: Alzinova meddelar positiva samtal med FDA | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-09 | Alzinova | Alzinova progresses following positive Pre-IND meeting with FDA | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-09 | Alzinova | Alzinova avancerar efter positivt Pre-IND-möte med FDA | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-03 | Alzinova | Alzinova recruits Kirsten Harting as new Chief Medical Officer | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-03 | Alzinova | Alzinova rekryterar Kirsten Harting som ny Chief Medical Officer | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-16 | Alzinova | BioStock: Alzinovas vd om kontakterna med FDA och EMA - BioStock | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-13 | Alzinova | Alzinova submits request for Pre-IND meeting with FDA and applies for EMA Scientific Advice | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-13 | Alzinova | Alzinova ansöker om Pre-IND möte med FDA och EMA Scientific Advice | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-30 | Alzinova | Bulletin from the annual general meeting of Alzinova AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-30 | Alzinova | Kommuniké från årsstämma i Alzinova AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-29 | Alzinova | First patient dosed in the extension part of the phase 1b study with ALZ-101 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-29 | Alzinova | Första patienten doserad i förlängningsdelen av fas 1b studien med ALZ-101 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-17 | Redeye | Redeye: Alzinova Q1 2023 - Promising clinical progress | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-17 | Alzinova | Alzinova AB interim report January – March 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-17 | Alzinova | Alzinova AB delårsrapport för januari - mars 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-10 | Alzinova | BioStock: Fortsatt robusta interimdata i Alzinovas Alzheimerstudie | Pressreleaser | Visa Stäng | ||||||||||||||
|